Novo Nordisk Options Trading: A Deep Dive Into Market Sentiment
Novo Nordisk Options Trading: A Deep Dive Into Market Sentiment
Financial giants have made a conspicuous bullish move on Novo Nordisk. Our analysis of options history for Novo Nordisk (NYSE:NVO) revealed 12 unusual trades.
金融巨頭對諾和諾德採取了明顯的看漲舉動。我們對諾和諾德（紐約證券交易所代碼：NVO）期權歷史的分析顯示了12筆不尋常的交易。
Delving into the details, we found 66% of traders were bullish, while 33% showed bearish tendencies. Out of all the trades we spotted, 4 were puts, with a value of $220,662, and 8 were calls, valued at $807,070.
深入研究細節，我們發現66％的交易者看漲，而33％的交易者表現出看跌趨勢。在我們發現的所有交易中，有4筆是看跌期權，價值220,662美元，8筆是看漲期權，價值807,070美元。
Projected Price Targets
預計價格目標
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $90.0 to $150.0 for Novo Nordisk over the last 3 months.
考慮到這些合約的交易量和未平倉合約，在過去的3個月中，鯨魚似乎一直將Novo Nordisk的價格定在90.0美元至150.0美元之間。
Volume & Open Interest Development
交易量和未平倉合約的發展
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Novo Nordisk's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Novo Nordisk's significant trades, within a strike price range of $90.0 to $150.0, over the past month.
檢查交易量和未平倉合約爲股票研究提供了至關重要的見解。這些信息是衡量Novo Nordisk期權在特定行使價下的流動性和利息水平的關鍵。下面，我們簡要介紹了過去一個月諾和諾德重大交易的看漲期權和未平倉合約的趨勢，行使價區間爲90.0美元至150.0美元。
Novo Nordisk Call and Put Volume: 30-Day Overview
Novo Nordisk 看漲和看跌交易量：30 天概述
Biggest Options Spotted:
發現的最大選擇：
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NVO | CALL | TRADE | BULLISH | 08/16/24 | $4.45 | $4.3 | $4.45 | $135.00 | $511.7K | 759 | 541 |
| NVO | PUT | SWEEP | BEARISH | 08/16/24 | $6.8 | $6.7 | $6.7 | $135.00 | $97.7K | 1.4K | 17 |
| NVO | CALL | TRADE | BULLISH | 09/20/24 | $3.4 | $3.3 | $3.4 | $145.00 | $86.0K | 7.8K | 6 |
| NVO | PUT | TRADE | BULLISH | 08/16/24 | $14.2 | $14.05 | $14.11 | $145.00 | $56.4K | 791 | 50 |
| NVO | CALL | SWEEP | BULLISH | 08/16/24 | $6.9 | $6.85 | $6.9 | $130.00 | $37.9K | 1.4K | 80 |
| 符號 | 看跌/看漲 | 交易類型 | 情緒 | Exp。日期 | 問 | 出價 | 價格 | 行使價 | 總交易價格 | 未平倉合約 | 音量 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NVO | 打電話 | 貿易 | 看漲 | 08/16/24 | 4.45 美元 | 4.3 美元 | 4.45 美元 | 135.00 美元 | 511.7 萬美元 | 759 | 541 |
| NVO | 放 | 掃 | 粗魯的 | 08/16/24 | 6.8 美元 | 6.7 美元 | 6.7 美元 | 135.00 美元 | 97.7 萬美元 | 1.4K | 17 |
| NVO | 打電話 | 貿易 | 看漲 | 09/20/24 | 3.4 美元 | 3.3 美元 | 3.4 美元 | 145.00 美元 | 86.0 萬美元 | 7.8K | 6 |
| NVO | 放 | 貿易 | 看漲 | 08/16/24 | 14.2 美元 | 14.05 美元 | 14.11 美元 | 145.00 美元 | 56.4 萬美元 | 791 | 50 |
| NVO | 打電話 | 掃 | 看漲 | 08/16/24 | 6.9 美元 | 6.85 美元 | 6.9 美元 | 130.00 美元 | 37.9 萬美元 | 1.4K | 80 |
About Novo Nordisk
關於 Novo Nordisk
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
諾和諾德擁有全球品牌糖尿病治療市場約三分之一的份額，是全球領先的糖尿病護理產品提供商。該公司總部位於丹麥，生產和銷售各種人用和現代胰島素、注射型糖尿病治療藥物（如 GLP-1 療法）、口服抗糖尿病藥物和肥胖療法。Novo還有一個生物製藥板塊（約佔收入的10％），專門研究血友病和其他疾病的蛋白質療法。
Following our analysis of the options activities associated with Novo Nordisk, we pivot to a closer look at the company's own performance.
在分析了與Novo Nordisk相關的期權活動之後，我們將轉向仔細研究公司自身的表現。
Current Position of Novo Nordisk
諾和諾德的當前位置
- With a volume of 2,060,022, the price of NVO is up 2.15% at $132.78.
- RSI indicators hint that the underlying stock may be approaching oversold.
- Next earnings are expected to be released in 19 days.
- NVO的交易量爲2,060,022美元，價格上漲2.15％，至132.78美元。
- RSI 指標暗示標的股票可能已接近超賣。
- 下一份業績預計將在19天后公佈。
What Analysts Are Saying About Novo Nordisk
分析師對諾和諾德的看法
In the last month, 3 experts released ratings on this stock with an average target price of $161.0.
上個月，3位專家發佈了該股的評級，平均目標價爲161.0美元。
- An analyst from Cantor Fitzgerald downgraded its action to Overweight with a price target of $160.
- An analyst from Cantor Fitzgerald has revised its rating downward to Overweight, adjusting the price target to $160.
- Consistent in their evaluation, an analyst from BMO Capital keeps a Outperform rating on Novo Nordisk with a target price of $163.
- 坎託·菲茨傑拉德的一位分析師將其評級下調至增持，目標股價爲160美元。
- 坎託·菲茨傑拉德的一位分析師已將其評級下調至增持，將目標股價調整爲160美元。
- BMO Capital的一位分析師在評估中保持了對諾和諾德跑贏大盤的評級，目標價爲163美元。
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
與僅交易股票相比，期權是一種風險更高的資產，但它們具有更高的獲利潛力。嚴肅的期權交易者通過每天自我教育、擴大交易規模、關注多個指標以及密切關注市場來管理這種風險。
譯文內容由第三人軟體翻譯。